Kindly Health - KDLY Price-to-Projected Revenue Ratio

Corporate emblem and logo of Kindly MD, Inc. (KDLY)

Is it worth investing in Kindly MD, Inc. (KDLY), a company that profits from chronic pain therapy and the administration of US insurance plans? This chart on GURU.Markets illustrates the business's forward P/S, where the 2.50 level captures the latest values. Growth is driven by partnerships with insurers to implement telemedicine, while a closed ecosystem of holistic treatment ensures stable patient retention under regulatory oversight.

KDLY (Kindly MD Inc) Market Cap to Future Revenue Ratio history from 06/01/2024 to 11/16/2026

Summary analytical data breakdowns for Kindly MD, Inc. (KDLY)

- current price and projected stock value:
Fundamental company valuation:Kindly MD Corp (KDLY)
Original product of Kindly Health

Forward P/S measures the market value of a business relative to expected revenue, allowing for the determination of whether quotes are overvalued relative to operational plans. For the micro-cap Kindly MD (KDLY) with a limited scaling history, the forward P/S multiple serves as a risk indicator: excessive growth of the ratio coupled with a failure to meet guidance threatens a stock collapse, whereas moderate values confirm a margin of safety.

Key competitors

Forward P/S Multiple HCA (HCA Healthcare, Inc.)|Price to Expected Revenue Ratio THC (Tenet Healthcare)|FMS - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio solventum.com|EHC: Forward P/S Multiple|UHS - Market Cap to Expected Sales Ratio|DVA (DaVita Corp) - Forward P/S Multiple|RDNT: Forward Price to Sales|Forward P/S Multiple OPCH|SGRY (surgerypartners.com) - Forward Price to Sales|Forward P/S Multiple PINC (Premier Inc)|National Vision - Price-to-Projected Revenue Ratio|PGNY - Price-to-Projected Revenue Ratio|ARDT - Forward P/S Multiple|SEM: Forward P/S Multiple|astranahealth.com (ASTH) - Forward P/S Multiple|MD (mednax.com) - Forward P/S Multiple|Forward P/S Multiple usph.com|Forward P/S Multiple PNTG|Market Cap to Expected Sales Ratio Organogenesis Holdings|Forward P/S Multiple NUTX (nutexhealth.com)|Auna SA (AUNA) - Market Cap to Future Revenue Ratio|SBC: Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio Jeuveau EOLS|CYH (Community Health Systems Inc) - Forward Price-to-Revenue Multiple|SKIN: Price to Expected Revenue Ratio|Forward Price-to-Revenue Multiple MDWD|BTMD: Forward Price to Sales|Price-to-Projected Revenue Ratio The Joint Corporation (JYNT)|Forward P/S Multiple DocGo Inc (DCGO)|Forward Price to Sales P3 Health Partners, Inc.|Market Cap to Expected Sales Ratio gaintherapeutics.com (GANX)|EUDA: Forward Price-to-Revenue Multiple|BMGL: Price-to-Projected Revenue Ratio|collplant.com (CLGN) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Cuprina Holdings|CCM (concordmedical.com) - Forward P/S Multiple|Forward P/S Multiple ASHS|Price-to-Projected Revenue Ratio MEDIROM (MRM)|ALBT - Market Cap to Future Revenue Ratio|DIH Holding US, Inc. - Forward Price-to-Revenue Multiple|Projected Price to Revenue Carmell Therapeutics Corporation|NewGenIvf Corp - Forward P/S Multiple|ATI Physical Therapy, Inc. - Price to Expected Revenue Ratio|CMAX: Forward P/S Multiple|Market Cap to Projected Revenue MODV|Price-to-Projected Revenue Ratio Novo Integrated Sciences Corp|Market Cap to Future Revenue Ratio SunLink Health Systems SSY|Price-to-Projected Revenue Ratio IMAC Corp (BACK)